AR110089A1 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- AR110089A1 AR110089A1 ARP170103184A ARP170103184A AR110089A1 AR 110089 A1 AR110089 A1 AR 110089A1 AR P170103184 A ARP170103184 A AR P170103184A AR P170103184 A ARP170103184 A AR P170103184A AR 110089 A1 AR110089 A1 AR 110089A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- cr6r7
- independently selected
- 6haloalkyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto, caracterizado porque presenta la estructura de la fórmula (1); en donde: R¹ es -R¹⁴, -OR³, -SR⁴, -S(O)₂R⁴, -N(R⁴)(R⁵), -NH(R⁴) o -CºC-(CR⁶R⁷)-R⁸; cada R² se selecciona de manera independiente entre C₁₋₆alquilo, halógeno, -CN, C₁₋₆haloalquilo, -C₁₋₆alquil(heterocicloalquilo), -OR¹⁷ y -C(O)NR¹⁸R¹⁹; R³ es -(CR⁶R⁷)ₘ-R⁸, -(CR⁶R⁷)ₚ-Y-(CR⁶R⁷)q-R⁸ o -(CR⁶R⁷)ₜ-C₃₋₆cicloalquil-R⁸; R⁴ es -(CR⁶R⁷)ₘ-R⁸, -(CR⁶R⁷)ᵛ-C(O)OH o -(CR⁶R⁷)ₚ-Y-(CR⁶R⁷)q-R⁸; R⁴ es -(CR⁶R⁷)ₘ-R⁸, -(CR⁶R⁷)ₚ-Y-(CR⁶R⁷)q-R⁸, -C₄₋₆alquil-C(O)OH, -C₃₋₆cicloalquil-C(O)OH o -C₁₋₆alquil-C₃₋₆cicloalquil-C(O)OH; Y es -O- o -N(R²²)-; R⁵ es C₁₋₆alquilo o -CH₂-fenilo sustituido opcionalmente con uno, dos o tres grupos seleccionados de manera independiente entre halógeno, C₁₋₆alquilo, C₁₋₆haloalquilo y C₁₋₆alcoxi; cada R⁶ y R⁷ se selecciona de manera independiente entre H, F y C₁₋₆alquilo; o R⁶ y R⁷ forman, junto con el carbono al cual están unidos, un anillo C₃₋₆cicloalquilo; R⁸ es -C(O)OR⁹, -C(O)R¹⁰ o -C(O)O-(CR¹²R¹³)-OC(O)R¹¹; R⁸ es -C(O)OR⁹, -C(O)R¹⁰ o -C(O)O-(CR¹²R¹³)-OC(O)R¹¹; R⁹ es H o C₁₋₆alquilo; R⁹ es C₁₋₆alquilo; R¹⁰ es C₁₋₆alquilo o -NHSO₂R²¹; R¹⁰ es C₂₋₆alquilo o -NHSO₂R²¹; R¹¹ es C₁₋₆alquilo o C₁₋₆alcoxi; R¹² y R¹³ es, cada uno de manera independiente, H o C₁₋₆alquilo; R¹⁴ es -(CR¹⁵R¹⁶)ₘ-R⁸ o -(CR⁶R⁷)ₚ-Y-(CR⁶R⁷)q-R⁸; cada R¹⁵ y R¹⁶ se selecciona de manera independiente entre H, F y C₁₋₆alquilo; cada R¹⁷ se selecciona de manera independiente entre H, C₁₋₆alquilo, C₁₋₆haloalquilo y C₃₋₆cicloalquilo; cada R¹⁸ y R¹⁹ se selecciona de manera independiente entre H, C₁₋₆alquilo, C₃₋₆cicloalquilo, arilo y heteroarilo; o R¹⁸ y R¹⁹ forman, junto con el nitrógeno al cual están unidos, un anillo heterocicloalquilo sustituido opcionalmente con uno, dos o tres R²⁰; cada R²⁰ se selecciona de manera independiente entre halógeno, C₁₋₆alquilo, C₁₋₆haloalquilo, oxo, -CN y C₃₋₆cicloalquilo; R²¹ es C₁₋₆alquilo o C₃₋₆cicloalquilo; R²² es H, C₁₋₆alquilo o -SO₂R²³; R²³ es C₁₋₆alquilo; m es 1, 2, 3 ó 4; n es 0, 1, 2, 3 ó 4; p es 2, 3 ó 4; q es 1, 2 ó 3; t es 0, 1 ó 2; y v es 3 ó 4; o una sal o un solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423099P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110089A1 true AR110089A1 (es) | 2019-02-20 |
Family
ID=62106678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103184A AR110089A1 (es) | 2016-11-16 | 2017-11-15 | Inhibidores de magl |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10093635B2 (es) |
| EP (1) | EP3541821A4 (es) |
| JP (1) | JP7042547B2 (es) |
| KR (1) | KR20190077544A (es) |
| CN (1) | CN110267963B (es) |
| AR (1) | AR110089A1 (es) |
| AU (1) | AU2017361251B2 (es) |
| BR (1) | BR112019009994A2 (es) |
| CA (1) | CA3043615A1 (es) |
| CL (1) | CL2019001339A1 (es) |
| CO (1) | CO2019005059A2 (es) |
| CR (1) | CR20190241A (es) |
| DO (1) | DOP2019000122A (es) |
| EA (1) | EA038090B1 (es) |
| EC (1) | ECSP19035077A (es) |
| GE (1) | GEP20237470B (es) |
| IL (1) | IL266523B (es) |
| JO (1) | JOP20190106A1 (es) |
| MA (1) | MA46857A (es) |
| MX (1) | MX2019005776A (es) |
| NI (1) | NI201900051A (es) |
| PE (1) | PE20191144A1 (es) |
| PH (1) | PH12019501097A1 (es) |
| RU (1) | RU2754536C1 (es) |
| TN (1) | TN2019000153A1 (es) |
| TW (1) | TWI756299B (es) |
| UA (1) | UA124542C2 (es) |
| WO (1) | WO2018093947A1 (es) |
| ZA (1) | ZA201903100B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982266B (zh) | 2012-01-06 | 2021-07-30 | H.隆德贝克有限公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| WO2018053447A1 (en) | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| PT3541807T (pt) | 2016-11-16 | 2021-12-09 | H Lundbeck As | Uma forma cristalina de um inibidor de magl |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
| FI3630744T3 (fi) | 2017-05-23 | 2023-03-21 | H Lundbeck As | MAGL:n pyratsoli-inhibiittoreita |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| TW201946906A (zh) * | 2018-05-15 | 2019-12-16 | 美商阿拜德生物製藥公司 | Magl抑制劑 |
| CN113330005A (zh) * | 2019-01-25 | 2021-08-31 | H.隆德贝克有限公司 | 用magl抑制剂治疗疾病的方法 |
| CA3159391A1 (en) * | 2019-11-15 | 2021-05-20 | H. Lundbeck A/S | Crystalline forms of a magl inhibitor |
| IT202000007150A1 (it) * | 2020-04-03 | 2021-10-03 | Univ Pisa | Inibitori di monoacilglicerolo lipasi (magl) |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (es) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
| WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| AU1384795A (en) | 1993-12-22 | 1995-07-10 | Shell Internationale Research Maatschappij B.V. | Process for preparing carbamates |
| AU7579696A (en) | 1995-11-15 | 1997-06-05 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| EP1218544B1 (en) | 1999-10-04 | 2009-06-03 | The University of Medicine and Dentistry of New Jersey | TAR RNA binding peptides |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| TW200531694A (en) | 2004-02-18 | 2005-10-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| CN101830899A (zh) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用 |
| DK2937341T3 (en) | 2004-12-30 | 2017-09-11 | Janssen Pharmaceutica Nv | 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS |
| EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| JP5576874B2 (ja) | 2008-11-14 | 2014-08-20 | ザ スクリプス リサーチ インスティテュート | モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 |
| KR20110131302A (ko) | 2009-03-23 | 2011-12-06 | 엠에스디 가부시키가이샤 | 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 |
| AU2010238732B2 (en) | 2009-04-22 | 2015-06-11 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| CN102667934B (zh) | 2009-11-03 | 2015-09-09 | 拜尔材料科学股份公司 | 作为光聚合物制剂中的添加剂的氟代氨基甲酸酯 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| CN107982266B (zh) * | 2012-01-06 | 2021-07-30 | H.隆德贝克有限公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015003002A1 (en) * | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| MX2017011997A (es) * | 2015-03-18 | 2018-05-28 | Abide Therapeutics Inc | Carbamatos de piperacina y metodos de preparacion y uso. |
| WO2018053447A1 (en) | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-06-16 JO JOP/2019/0106A patent/JOP20190106A1/ar unknown
- 2017-11-15 BR BR112019009994A patent/BR112019009994A2/pt unknown
- 2017-11-15 US US15/814,322 patent/US10093635B2/en active Active
- 2017-11-15 WO PCT/US2017/061868 patent/WO2018093947A1/en active Application Filing
- 2017-11-15 PE PE2019001014A patent/PE20191144A1/es unknown
- 2017-11-15 AU AU2017361251A patent/AU2017361251B2/en not_active Ceased
- 2017-11-15 AR ARP170103184A patent/AR110089A1/es unknown
- 2017-11-15 GE GEAP201715088A patent/GEP20237470B/en unknown
- 2017-11-15 CN CN201780083663.6A patent/CN110267963B/zh active Active
- 2017-11-15 JP JP2019523587A patent/JP7042547B2/ja active Active
- 2017-11-15 IL IL266523A patent/IL266523B/en unknown
- 2017-11-15 MX MX2019005776A patent/MX2019005776A/es unknown
- 2017-11-15 EP EP17871753.4A patent/EP3541821A4/en not_active Withdrawn
- 2017-11-15 RU RU2019116512A patent/RU2754536C1/ru active
- 2017-11-15 EA EA201991073A patent/EA038090B1/ru unknown
- 2017-11-15 TN TNP/2019/000153A patent/TN2019000153A1/en unknown
- 2017-11-15 UA UAA201905620A patent/UA124542C2/uk unknown
- 2017-11-15 KR KR1020197016924A patent/KR20190077544A/ko active IP Right Grant
- 2017-11-15 CR CR20190241A patent/CR20190241A/es unknown
- 2017-11-15 CA CA3043615A patent/CA3043615A1/en active Pending
- 2017-11-15 MA MA046857A patent/MA46857A/fr unknown
- 2017-11-16 TW TW106139775A patent/TWI756299B/zh active
-
2019
- 2019-05-16 EC ECSENADI201935077A patent/ECSP19035077A/es unknown
- 2019-05-16 CL CL2019001339A patent/CL2019001339A1/es unknown
- 2019-05-16 PH PH12019501097A patent/PH12019501097A1/en unknown
- 2019-05-16 DO DO2019000122A patent/DOP2019000122A/es unknown
- 2019-05-16 NI NI201900051A patent/NI201900051A/es unknown
- 2019-05-16 CO CONC2019/0005059A patent/CO2019005059A2/es unknown
- 2019-05-17 ZA ZA201903100A patent/ZA201903100B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110089A1 (es) | Inhibidores de magl | |
| AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| AR110405A1 (es) | Compuestos | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR123089A2 (es) | Compuesto de piridinona | |
| AR109905A1 (es) | Pirrolidinas sustituidas como moduladores de cftr | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100879A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR086817A1 (es) | Compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR098492A1 (es) | Derivados de purina | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| AR113886A1 (es) | Derivados de indol macrocíclicos |